Bioarctic Ab Class B · OMXSTO:BIOA_B
Bioarctic Ab Class B — FY2020 Earnings Presentation
16 slides from Bioarctic Ab Class B's earnings presentation, Feb 4, 2021
Slide 1: Full Year Report January-December 2020
BIOARCTIC AB (PUBL) NASDAQ STOCKHOLM: BIOA B Full Year Report January-December 2020 Stockholm, February 4, 2021 Gunilla Osswald, PhD, CEO Jan Mattsson, CFO BioArctic AB
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such
Slide 3: BioArctic – a unique Swedish biopharma company
BioArctic – a unique Swedish biopharma company Improving life for patients with central nervous system disorders High unmet need for disease-modifying treatments for Alzheimer’s and Parkinson’s diseases creates large commercial opportunity World-class research and development driven organization wit
Slide 4: 2020 in summary
2020 in summary Lecanemab (BAN2401) • Phase 2b open-label extension study in early AD: • Data presented at several congresses supports the encouraging Phase 2b data • Phase 3 confirmatory study Clarity AD in early AD: • Progressed well and Eisai mitigated potential impact of COVID-19 • Phase 3 AHEAD
Slide 5: Q4 highlights: New data further supports lecanemab (BAN2401)
Q4 highlights New data further supports lecanemab (BAN2401) Lecanemab (BAN2401) • Lecanemab was assigned as the International Nonproprietary Name (INN) for BAN2401 • Presentations at CTAD congress : • Clarity AD Phase 3: • Baseline characteristics consistent with Phase 2b, and representative of an e
Slide 6: Attractive and well-balanced project portfolio combines partner and proprietary projects
Attractive and well-balanced project portfolio combines fully- financed partner projects and cutting-edge proprietary projects Project Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 ALZHEIMER’S DISEASE Lecanemeb (BAN2401) (Clarity AD) Eisai1 Early Alzheimer’s disease4 Lecanemab (BAN2401) (AHE
Slide 7: Long-standing and extensive partnerships
Long-standing and extensive partnerships Alzheimer’s disease Parkinson’s disease Partner track record Collaboration and license Partner track record Collaboration and license MEUR 65 MUSD 130 received World’s all-time best-selling received Discovered and developed medicine (BUSD 20) world’s best-sel
Slide 8: Broad lecanemab clinical program – driven by BioArctic's partner Eisai
Broad lecanemab clinical program – driven by BioArctic’s partner Eisai Disease stage Preclinical AD MCI Mild AD Moderate Severe FDA guideline Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 AHEAD 3-45 Phase 3 Program – Clarity AD Phase 3 confirmatory ongoing study – ongoing • Eisai and ACTC started
Slide 9: Early-stage portfolio continues to develop well
Early-stage portfolio continues to develop well Alzheimer’s disease Parkinson’s disease Other CNS disorders Blood-brain barrier Diagnostics technology Discovery stage Discovery stage Neurodegeneration Blood-brain barrier Diagnostics programs projects research technology platform • Continued • 4 full
Slide 10: Financial Summary
Financial Summary 10 BioArctic AB
Slide 11: Net revenues and operating profit/loss Q4 2020
Net revenues and operating profit/loss Q4 2020 Net Revenues (MSEK) OPEX by item (MSEK) Operating Profit/Loss (MSEK) 171 60 53 48 44 43 40 40 40 36 32 63 127 36 20 21 26 7 11 8 17 -11 -21 4 -38 -21 -30 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 Proje
Slide 12: Cash and net result Q4 2020
Cash and net result Q4 2020 Cash Balance (MSEK) Cash Flow From Operating Net Result (MSEK) Activities (MSEK) 1 256 1 218 1 170 334 1 113 1 077 1 050 1 036 1 000 97 100 -49 -54 -36 -20 -9 -25 14 -8 -17 4 -38 -21 -13 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 2020 201
Slide 13: Upcoming news and closing remarks
Upcoming news and closing remarks 13 BioArctic AB
Slide 14: Upcoming news flow
Upcoming news flow Alzheimer’s disease Parkinson’s disease Other CNS disorders Blood-brain barrier Diagnostics technology Lecanemab (Eisai) ABBV-0805 (AbbVie) Neurodegeneration Blood-brain barrier Diagnostics • To present data at • Complete Phase 1 research technology platform • Continue internation
Slide 15: BioArctic: With Patients in Mind
BioArctic: With Patients in Mind Built on science Projects in focus Value-driven leadership Great science Great projects Great people 15 BioArctic AB
Slide 16: Contact and investor relations information
GUNILLA OSSWALD, CEO JAN MATTSSON, CFO OSKAR BOSSON, VP NEXT REPORT & IR COMMUNICATIONS & IR CONTACT • Next Report: Q1 2021 Jan-Mar 2021 on April 21, 2021 • Contact: Oskar Bosson, VP Communications & IR +46 704 10 71 80 ir@bioarctic.se To subscribe to financial reports/press releases and for more in